In 2024, 5,565 people in England and Wales died from drug poisoning the highest number since records began. UK drug deaths have now risen for fourteen consecutive years. The mortality rate has more than doubled since 2012.

Let that sit for a moment. Fourteen years of consecutive increases, of strategies, announcements, working groups, and spending commitments. Fourteen years of a death toll that has kept climbing regardless.

The Government’s response has been to point to the progress within its “From Harm to Hope” 10-year strategy. County lines closed. Drug workers recruited. Investment committed. These things are real. They are also insufficient. Because the headline number keeps rising, and the people behind it keep dying, and the one intervention that has demonstrably saved lives in Glasgow is the one Britain’s drug policy refuses to endorse anywhere else.

What the UK Drug Death Numbers Actually Say

The ONS drug poisoning data for 2024 tells a story Britain’s drug policy has not managed to interrupt.

Cocaine-related deaths reached 1,279 in 2024, a 14.4 per cent increase and the thirteenth consecutive annual rise. In 2011, cocaine deaths were recorded in the tens. They are now in the thousands. That trajectory did not happen by accident. It happened in the context of a drug supply that has become more accessible, more potent, and more adulterated, while prevention investment has struggled to keep pace.

The Generation X cohort, those now aged 40 to 49, carries the highest UK drug death burden. These are people who began using drugs in the 1980s and 1990s, when the cultural narrative was that experimentation was normal and the long-term consequences were someone else’s problem. Decades later, they are the ones dying. Many of them have been in and out of treatment systems that were not built for long-term, complex dependency. Many of them never accessed treatment at all.

The most alarming data point in the 2024 figures is nitazenes. Deaths involving these synthetic opioids quadrupled between 2023 and 2024, reaching 195. Not a household name yet, but they should be. Some are estimated to be up to 100 times more potent than heroin, cheap to synthesise, and easy to cut into existing supply chains. Standard drug-checking methods frequently cannot detect them. There are no geographic origins to target, no trafficking routes to disrupt. What is arriving in Britain’s illicit supply right now is the next chapter of the synthetic opioid crisis that has already killed tens of thousands in the United States.

“From Harm to Hope” has delivered some of what it promised. By 2022-23, 1,417 county lines had been closed and 1,224 new drug and alcohol workers had been recruited, exceeding the original target of 950. Those are genuine achievements. But 5,565 UK drug deaths in a single year is not a sign that Britain’s drug policy is working at the scale the crisis demands.

Glasgow Opened a Facility That Cut UK Drug Deaths. The Government Won’t Follow.

In January 2025, Glasgow opened The Thistle, the first sanctioned safer drug consumption facility in the United Kingdom. It operates under a statement of prosecutorial discretion from the Lord Advocate, meaning people who use the facility will not be prosecuted for possession while on the premises.

In its first year, The Thistle recorded 11,348 visits. Staff managed 93 medical emergencies. Not one person died.

Ninety-three overdoses. Zero UK drug deaths on site.

That outcome is not luck. It is the direct result of having trained staff present at the moment a drug-related emergency occurs, with the tools and the authority to intervene. Many of those 93 people would likely have died alone. In a stairwell, a toilet cubicle, a park. Because there was no one there.

Britain’s drug policy at the Home Office level holds that safer drug consumption facilities do not align with the national strategy. The strategy prioritises enforcement and treatment over what it frames as harm facilitation. That framing is ideologically coherent but empirically costly. It means that the model operating in Glasgow, which has a higher drug death rate per capita than anywhere else in Europe, is permitted to continue as a pilot while being explicitly blocked from expanding to cities like Bristol, where advocacy groups have been pushing for a similar facility for years.

The disconnect here is significant. Scotland is producing the evidence. England is looking away.

You can read the full account of The Thistle’s first year atTransform Drug Policy Foundationand the NHS Greater Glasgow and Clydefirst year report.

The Medical Cannabis Contradiction in Britain’s Drug Policy

Quietly, Britain’s drug policy regulatory environment for medicinal substances is shifting. The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 streamline approvals for new therapies including psychedelics and cannabis-based medicinal products. The private medical cannabis market has grown substantially, with prescriptions doubling to 177,566 items in 2023.

But NHS access remains extremely limited. The people most likely to benefit from cannabis-based treatment for chronic pain, anxiety, and PTSD-adjacent conditions are frequently the same people who cannot afford private prescriptions. So a treatment option that exists in law is effectively rationed by cost, a recurring pattern in how Britain’s drug policy serves those most at risk.

The Advisory Council on the Misuse of Drugs launched a formal review in late 2025 of the 2018 changes to the Misuse of Drugs Regulations, examining whether the existing framework adequately meets patient needs. That review is welcome. What it signals, though, is that regulatory policy has not kept pace with clinical reality.

Prevention Is Not a Supplement to Britain’s Drug Policy. It Is the Missing Centre of It.

“From Harm to Hope” is a strategy that does many things — closes criminal networks, funds treatment, recruits workers. What it does not do, at the scale required, is prevent drug use from beginning in the first place.

The people behind the UK drug death statistics today largely began using drugs before any of these strategies existed. The people who will die in ten years are using drugs now, or are already in the conditions that make drug use likely: disconnection, trauma, economic instability, educational failure, and a social environment that normalises substance use without naming the risk.

Prevention investment that reaches young people before drug use begins, that builds family resilience, that addresses the underlying conditions of vulnerability, does not produce statistics you can report in an annual strategy update. Its success is measured in things that did not happen. That makes it politically invisible and chronically underfunded within Britain’s drug policy planning cycle.

UK drug deaths are rising. Scotland is demonstrating what happens when you meet people where they are with skilled, compassionate intervention. The Home Office is watching from a distance and calling it a pilot.

5,565 families in 2024 would like a different answer.